JP2022553540A - 操作された制御性ｔ細胞 - Google Patents

操作された制御性ｔ細胞 Download PDF

Info

Publication number
JP2022553540A
JP2022553540A JP2022523913A JP2022523913A JP2022553540A JP 2022553540 A JP2022553540 A JP 2022553540A JP 2022523913 A JP2022523913 A JP 2022523913A JP 2022523913 A JP2022523913 A JP 2022523913A JP 2022553540 A JP2022553540 A JP 2022553540A
Authority
JP
Japan
Prior art keywords
tcr
cells
seq
tregs
foxp3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022523913A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553540A5 (https=
Inventor
ハンス シュタウス，
シャリン トーマス，
オリビエ プレハム，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201915362A external-priority patent/GB201915362D0/en
Priority claimed from GB201915366A external-priority patent/GB201915366D0/en
Priority claimed from GB201915354A external-priority patent/GB201915354D0/en
Priority claimed from GB201915344A external-priority patent/GB201915344D0/en
Priority claimed from GB201915341A external-priority patent/GB201915341D0/en
Priority claimed from GB201915360A external-priority patent/GB201915360D0/en
Priority claimed from GB201915351A external-priority patent/GB201915351D0/en
Priority claimed from GB201915347A external-priority patent/GB201915347D0/en
Priority claimed from GB201915348A external-priority patent/GB201915348D0/en
Priority claimed from GB201915357A external-priority patent/GB201915357D0/en
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Publication of JP2022553540A publication Critical patent/JP2022553540A/ja
Publication of JP2022553540A5 publication Critical patent/JP2022553540A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rehabilitation Therapy (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
JP2022523913A 2019-10-23 2020-10-22 操作された制御性ｔ細胞 Pending JP2022553540A (ja)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
GB201915344A GB201915344D0 (en) 2019-10-23 2019-10-23 Engineered regulatory T cell
GB1915347.7 2019-10-23
GB201915341A GB201915341D0 (en) 2019-10-23 2019-10-23 Engineered regulatory T cell
GB201915360A GB201915360D0 (en) 2019-10-23 2019-10-23 Engineered regulatory t cell
GB201915362A GB201915362D0 (en) 2019-10-23 2019-10-23 Engineered regulatory t cell
GB1915362.6 2019-10-23
GB1915341.0 2019-10-23
GB201915354A GB201915354D0 (en) 2019-10-23 2019-10-23 Engineered regulatory t cell
GB1915348.5 2019-10-23
GB201915351A GB201915351D0 (en) 2019-10-23 2019-10-23 Engineered regulatory t cell
GB201915357A GB201915357D0 (en) 2019-10-23 2019-10-23 Engineered regulatory t cell
GB1915366.7 2019-10-23
GB201915348A GB201915348D0 (en) 2019-10-23 2019-10-23 Engineered regulatory t cell
GB201915347A GB201915347D0 (en) 2019-10-23 2019-10-23 Engineered regulatory t cell
GB1915351.9 2019-10-23
GB1915354.3 2019-10-23
GB1915360.0 2019-10-23
GB201915366A GB201915366D0 (en) 2019-10-23 2019-10-23 Engineered regulatory t cell
GB1915357.6 2019-10-23
GB1915344.4 2019-10-23
PCT/GB2020/052659 WO2021079122A1 (en) 2019-10-23 2020-10-22 Engineered regulatory t cell

Publications (2)

Publication Number Publication Date
JP2022553540A true JP2022553540A (ja) 2022-12-23
JP2022553540A5 JP2022553540A5 (https=) 2023-10-19

Family

ID=73040143

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022523913A Pending JP2022553540A (ja) 2019-10-23 2020-10-22 操作された制御性ｔ細胞

Country Status (7)

Country Link
US (1) US20220364057A1 (https=)
EP (1) EP4048294A1 (https=)
JP (1) JP2022553540A (https=)
CN (1) CN114641564B (https=)
AU (1) AU2020370033A1 (https=)
CA (1) CA3154606A1 (https=)
WO (1) WO2021079122A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023050063A1 (zh) * 2021-09-28 2023-04-06 溧阳瑅赛生物医药有限公司 一种识别hla-a*02:01/e629-38的tcr及其应用
EP4568686A2 (en) * 2022-08-12 2025-06-18 Abata Therapeutics, Inc. Cell therapies for multiple sclerosis
WO2024039576A2 (en) * 2022-08-19 2024-02-22 Memorial Sloan-Kettering Cancer Center T cell receptors targeting ras mutations and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160194605A1 (en) * 2013-05-10 2016-07-07 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Design and use of specific regulatory t-cells to induce immune tolerance
JP2018506287A (ja) * 2015-02-16 2018-03-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｈｅｒ２／Ｎｅｕ （ＥＲＢＢ２）受容体タンパク質に由来する３６９〜３７７位エピトープに特異的な完全ヒトＴ細胞受容体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2825261B1 (fr) 2001-06-01 2003-09-12 Maco Pharma Sa Ligne de prelevement du sang placentaire comprenant une poche de rincage
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
GB0917094D0 (en) * 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160194605A1 (en) * 2013-05-10 2016-07-07 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Design and use of specific regulatory t-cells to induce immune tolerance
JP2018506287A (ja) * 2015-02-16 2018-03-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｈｅｒ２／Ｎｅｕ （ＥＲＢＢ２）受容体タンパク質に由来する３６９〜３７７位エピトープに特異的な完全ヒトＴ細胞受容体

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KATO ZENICHIRO ET AL.: ""The autoimmune TCR-Ob.2F3 can bind to MBP85-99/HLA-DR2 having an unconventional mode as in TCR-Ob.", MOLECULAR IMMUNOLOGY, vol. Vol. 48, No. 1-3, JPN6024039363, November 2010 (2010-11-01), pages 314 - 320, ISSN: 0005561525 *
KIM YONG CHAN ET AL.: ""Engineered MBP-specific human Tregs ameliorate MOG-induced EAE through IL-2-triggered inhibition o", JOURNAL OF AUTOIMMUNITY, vol. 92, JPN6024039362, August 2018 (2018-08-01), pages 77 - 86, ISSN: 0005426782 *
STEPHENS LEIGH A. ET AL.: ""Curing CNS autoimmune disease with myelin‐reactive Foxp3+ Treg"", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 39, no. 4, JPN6024039361, April 2009 (2009-04-01), pages 1108 - 1117, XP055595690, ISSN: 0005426783, DOI: 10.1002/eji.200839073 *
WRIGHT GRAHAM P. ET AL.: ""Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 106, no. 45, JPN6023006519, 10 November 2009 (2009-11-10), pages 19078 - 19083, XP055330489, ISSN: 0005561526, DOI: 10.1073/pnas.0907396106 *

Also Published As

Publication number Publication date
CN114641564B (zh) 2024-07-19
US20220364057A1 (en) 2022-11-17
CA3154606A1 (en) 2021-04-29
EP4048294A1 (en) 2022-08-31
CN114641564A (zh) 2022-06-17
WO2021079122A1 (en) 2021-04-29
AU2020370033A1 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
US20250154532A1 (en) Engineered regulatory t cell
US20220267406A1 (en) Method
CN114641564B (zh) 工程化的调节性t细胞
JP2022553379A (ja) 操作された制御性ｔ細胞
JP2025515116A (ja) 制御性ｔ細胞の抑制活性を維持するための方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231011

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241001

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250331